These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16700819)

  • 1. Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays.
    Karamperis N; Koefoed-Nielsen PB; Brahe P; Højskov C; Egfjord M; Poulsen JH; Jørgensen KA
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):569-74. PubMed ID: 16700819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients.
    Karamperis N; Koefoed-Nielsen P; Bagger Sørensen A; Højskov C; Poulsen J; Jørgensen K
    Nephrol Dial Transplant; 2005 Mar; 20(3):618-21. PubMed ID: 15671072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus.
    Akhlaghi F; Dostalek M; Falck P; Mendonza AE; Amundsen R; Gohh RY; Asberg A
    Ther Drug Monit; 2012 Feb; 34(1):38-45. PubMed ID: 22210099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Højskov C; Poulsen JH; Jørgensen KA
    Transpl Int; 2006 Oct; 19(10):821-7. PubMed ID: 16961774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
    Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
    Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor assay based on surface plasmon resonance for the assessment of the complex formation activity of cyclosporin A and its metabolites.
    Vollenbroeker B; Fobker M; Specht B; Bartetzko N; Erren M; Spener F; Hohage H
    Int J Clin Pharmacol Ther; 2003 Jun; 41(6):248-60. PubMed ID: 12816177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine Metabolites' Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens.
    Hryniewiecka E; Żegarska J; Żochowska D; Samborowska E; Jaźwiec R; Kosieradzki M; Nazarewski S; Dadlez M; Pączek L
    Cardiovasc Toxicol; 2019 Jun; 19(3):255-263. PubMed ID: 30471016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue.
    Ozbay A; Karamperis N; Jørgensen KA
    Curr Clin Pharmacol; 2007 Sep; 2(3):244-8. PubMed ID: 18690871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods.
    Hamwi A; Salomon A; Steinbrugger R; Fritzer-Szekeres M; Jäger W; Szekeres T
    Am J Clin Pathol; 2000 Oct; 114(4):536-43. PubMed ID: 11026099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole blood cyclosporin monitoring in liver and heart transplant patients: evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique.
    Gulbis B; Van der Heijden J; van As H; Thiry P
    J Pharm Biomed Anal; 1997 Apr; 15(7):957-63. PubMed ID: 9160262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine metabolite cross-reactivity in different cyclosporine assays.
    Murthy JN; Yatscoff RW; Soldin SJ
    Clin Biochem; 1998 Apr; 31(3):159-63. PubMed ID: 9629489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.
    Wallemacq P; Maine GT; Berg K; Rosiere T; Marquet P; Aimo G; Mengozzi G; Young J; Wonigeit K; Kretschmer R; Wermuth B; Schmid RW
    Ther Drug Monit; 2010 Apr; 32(2):145-51. PubMed ID: 20216110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus.
    Jørgensen KA; Koefoed-Nielsen PB; Karamperis N
    Scand J Immunol; 2003 Feb; 57(2):93-8. PubMed ID: 12588654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique.
    Ansermot N; Fathi M; Veuthey JL; Desmeules J; Rudaz S; Hochstrasser D
    Clin Biochem; 2008 Jul; 41(10-11):910-3. PubMed ID: 18358833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
    Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of cyclosporine A and its three metabolites AM1, AM9 and AM4N in whole blood and isolated lymphocytes in renal transplant patients.
    Brozmanová H; Perinová I; Halvová P; Grundmann M
    J Sep Sci; 2010 Aug; 33(15):2287-93. PubMed ID: 20589784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity.
    Fukudo M; Yano I; Masuda S; Okuda M; Inui K
    J Pharmacol Exp Ther; 2005 Feb; 312(2):816-25. PubMed ID: 15383634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation.
    Mortensen DM; Koefoed-Nielsen PB; Jørgensen KA
    Transplant Proc; 2006 Oct; 38(8):2651-3. PubMed ID: 17098028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics.
    Napoli KL
    Ther Drug Monit; 2006 Dec; 28(6):726-36. PubMed ID: 17164687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of instrumental, nonisotopic immunoassays (fluorescence polarization immunoassay and enzyme-multiplied immunoassay technique) for cyclosporine monitoring in whole blood after kidney and liver transplantation.
    Beutler D; Molteni S; Zeugin T; Thormann W
    Ther Drug Monit; 1992 Oct; 14(5):424-32. PubMed ID: 1448852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.